Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Trial Profile

Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APVO 210 (Primary)
  • Indications Plaque psoriasis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Aptevo Therapeutics
  • Most Recent Events

    • 03 Oct 2019 Status changed from recruiting to discontinued, according to an Aptevo Therapeutics media release. The decision followed the review of data from the Phase 1 multiple ascending dose (MAD) clinical study of APVO210 in healthy volunteers that suggests that APVO210 would not meet the desired target product profile for future commercialization.
    • 07 Aug 2019 According to an Aptevo Therapeutics media release, with preliminary top-line safety data from an autoimmune-focused bispecific antibody candidate, APVO210, recently showing encouraging results, prompting the initiation of the next stage of this phase I clinical trial-evaluating multiple ascending doses of APVO210.
    • 20 Mar 2019 According to an Aptevo Therapeutics media release, the company has commenced dosing in this trial. The study is expected to enroll a maximum of 64 subjects in the initial SAD dose cohort and up to 40 subjects in the MAD dose cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top